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Abstract
Atrial fibrillation is a common cause for stroke. Vitamin K antagonists
such as warfarin are an effective prophylactic medication to prevent
stroke in patients with atrial fibrillation. Warfarin, however, has a
narrow therapeutic index, reacts with certain foods, increases bleeding
risks, and requires frequent monitoring. New medications have been
developed to prevent clot formation while avoiding the negative effects
of warfarin. The purpose of this study was to compare direct factor Xa
inhibitors (rivaroxaban, apixaban, and edoxaban) versus warfarin in
stroke prevention, safety, and cost.
The review of literature analyzed studies comparing warfarin and direct
factor Xa inhibitors in patients with atrial fibrillation. Study outcomes
included stroke prevention, bleeding risks, and cost. Analysis on
antidote/reversal agents were also examined.
Direct factor Xa inhibitors decreased stroke compared with warfarin
with an odds reduction of 0.81 and decreased intracranial
hemorrhages with an odds reduction of 0.56 (Bruins & Berge, 2013).
Direct factor Xa inhibitors were more cost effective, but with higher out
of pocket expense. Direct factor Xa inhibitors have no reversal agent.
Despite no antidote, research showed lower rates of fatal bleeding
deaths associated with direct factor Xa inhibitor use compared to
warfarin.

Introduction
Atrial fibrillation is a common abnormal heart rhythm leading to
increased thrombus formation and stroke risk. Eckman (2016) states:
Atrial fibrillation (AF) is the most common significant cardiac rhythm
disorder and is also the most powerful common risk factor for stroke:
about 15% of all strokes in the U.S. are attributable to AF. (p. 234)
Vitamin K antagonists have long been used as an effective prophylactic
medication to prevent thrombus formation in patients with atrial
fibrillation. According to Santarpia, Curcio, Sibilio, and Indolfi (2015),
warfarin’s “effectiveness is proven by 64% relative risk reduction of
stroke compared with placebo, and it also shows superior results to
aspirin and to aspirin plus clopidogrel” (p. 914). Warfarin, while
effective at preventing thrombi, has several drawbacks associated with
its use. The direct factor Xa inhibitors have been developed in an
attempt to effectively anticoagulate patients while avoiding the negative
aspects of warfarin.

Literature Review
An online database search of
PubMed and Cochrane was
performed for scholarly
articles related to direct
factor Xa inhibitor use versus
warfarin in nonvalvular atrial
fibrillation. Specific searches
included efficacy of factor Xa
inhibitors versus warfarin for
stroke prevention, safety,
cost, and reversibility.

Cost:
• Amin et al. (2014) demonstrated cost savings with the direct factor Xa
inhibitors apixaban ($493) and rivaroxaban ($358) for stroke prevention.
In cost avoidance, excluding intracranial hemorrhage, apixaban saved
$752 while rivaroxaban cost more than warfarin by $502.

Table 1:

• Out of pocket expenses depends on insurance coverage. With no
insurance the cost of rivaroxaban is $347 for 20 mg tabs, $342 for 5 mg
apixaban tabs, and $290 for 60 mg edoxaban tabs. The cost of warfarin
is $13 for 5 mg tabs (Anticoagulants, 2015).
Reversibility:
• Despite no reversal agent Caldeira et al. (2015) completed a systematic
review and meta-analysis comparing hemorrhage related deaths of the
novel oral anticoagulants (NOACs) compared with warfarin. Results
demonstrated the NOACs had a 47% odds reduction for fatal bleeds in
patients with atrial fibrillation (odds reduction, 0.53, 95% CI, 0.42-0.68,
I2=0%, x2=3.85, Pheterogeneity=0.43).

Atrial fibrillation is a risk
factor for stroke and a
commonly used grading
scale to assess stroke risk in
atrial fibrillation is the
CHA2DS2-VASc score.

Warfarin is an effective anticoagulant but has several drawbacks to its
use including a narrow therapeutic index, reaction with foods
containing vitamin K, variable pharmacokinetics/pharmacodynamics
and increased risk of intracranial hemorrhage. These factors led to the
development of new medications such as the direct factor Xa inhibitors.

Research Questions
In patients with atrial fibrillation, do direct factor Xa inhibitors decrease
the risk of stroke and bleeding, and are the direct factor Xa inhibitors
cost effective when compared to warfarin? Are direct factor Xa
inhibitors reversible?

• Direct factor Xa inhibitors have favorable pharmacokinetics and
pharmacodynamics when compared to warfarin.
• Cost is a major concern with out of pocket expenses of direct factor
Xa inhibitors far exceeding that of warfarin.
• Despite no reversal agent, direct factor Xa inhibitors cause less
bleeding deaths when compared with warfarin.
Table 3:

Papadakis et al., 2015, p. 386

• Granger et al. (2011) compared apixaban and warfarin in stroke
prevention. Results demonstrated 1.60% had stroke or systemic
embolism on warfarin compared to 1.27% on apixaban (hazard ratio
for apixaban, 0.79, 95% CI, 0.66-0.95, P<0.001 for noninferiority,
P=0.01 for superiority).

Direct factor Xa inhibitors are efficacious at preventing both ischemic and
hemorrhagic stroke. Apixaban is superior to warfarin in stroke prevention
while rivaroxaban and edoxaban are non-inferior to warfarin. All three
direct factor Xa inhibitors cause less intracranial hemorrhage. Apixaban
had less bleeding risks associated with its use compared to warfarin.
Rivaroxaban had similar bleeding rates as warfarin but increased
gastrointestinal bleeding. Edoxaban demonstrated less overall bleeding
risk when compared to warfarin except increased gastrointestinal
bleeding in the high-dose form. No direct comparison studies of the
direct factor Xa inhibitors have been performed. Out of pocket costs of
the direct factor Xa inhibitors is high, however, direct factor Xa inhibitors
provided an overall cost savings with reduced number of strokes and
intracranial hemorrhages. The direct factor Xa inhibitors lack a reversal
agent, however, the direct factor Xa inhibitors are associated with lower
death rates when compared to warfarin.

Table 2:

• Patel et al. (2011) compared rivaroxaban and warfarin in stroke
prevention. Results demonstrated rivaroxaban had a stroke or
systemic embolism occurrence rate of 1.7% per year compared to
2.2% on warfarin (hazard ratio for rivaroxaban group, 0.79, 95% CI,
0.66 to 0.96, P<0.001 for noninferiority).
• Giugliano et al. (2013) compared edoxaban and warfarin for stroke
reduction and found high-dose edoxaban and warfarin had an equal
ischemic stroke risk of 1.25% per year (hazard ratio 1.00, 95% CI,
0.83 to 1.19, P<0.97).

Santarpia et al., 2015, p. 917
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Bleeding Risks:

Statement of the Problem

• Direct factor Xa inhibitors are effective in preventing stroke and have
similar or reduced bleeding risks when compared to warfarin. Direct
factor Xa inhibitors decrease the risk of intracranial hemorrhage.

Discussion

Stroke Prevention:
• Bruins and Berge (2013)
completed a systematic
review and found a
statistically significant
reduction of all types of
strokes for the factor Xa
inhibitors compared to
warfarin (odds ratio 0.78,
95% CI 0.69 to 0.89).

Applicability to Clinical
Practice

• Bruins and Berge (2013) found factor Xa inhibitors decreased
intracranial hemorrhage when compared to warfarin (odds ratio 0.51,
95% CI, 0.41-0.64, I2=0%). Factor Xa inhibitors decreased bleeding
risks versus warfarin with high heterogeneity (odds ratio 0.89, 95%
CI, 0.81-0.98, I2=81%).
• Miller, Grandi, Shimony, Filion, and Eisenberg (2012) demonstrated
the new oral anticoagulants reduced rates of intracranial hemorrhage
(RR, 0.49, 95% CI, 0.36-0.66). Rivaroxaban had similar major
bleeding risks while apixaban had less major bleeding risks when
compared to warfarin (RR, 0.88, 95% CI, 0.71-1.09). Rivaroxaban
was associated with higher gastrointestinal bleeding (RR 1.46, 95%
CI, 1.19-1.78).
• Giugliano et al. (2013) demonstrated warfarin had a major bleeding
occurrence rate of 3.43% per year while 60 mg edoxaban had major
bleeding occurrence rate of 2.75% per year (hazard ratio, 0.80, 95%
CI, 0.71-0.91, P<0.001). High-dose edoxaban was associated with
higher rates of gastrointestinal bleeding (1.51% versus 1.23% in the
warfarin group) (hazard ratio, 1.23, 95% CI, 1.02-1.50, P
Value=0.03).

Santarpia et al., 2015, p. 918
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